Nanoviricides Stock News

NanoViricides (NYSE-A:NNVC) announced that its lead drug asset NV-387 has shown ultra-broad antiviral activity, including against Influenza A viruses.   The company said that in a lethal animal mode

NV-387 Possesses Strong Anti-Influenza-A Virus Activity, and May Have Activity Against H5N1 Bird Flu Virus, Says NanoViricides SHELTON, CT / ACCESSWIRE / May 6, 2024 / NanoViricides, Inc. (NYSE Americ

  SHELTON, CT -- May 2, 2024 -- InvestorsHub NewsWire -- NanoViricides, Inc. (NYSE Amer: NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully and data lock is expected soon. The Phase 1 clinical trial, protocol number KM-NVCoV2-001, which received approval from the regulatory agency in India for healthy as well as COVID-19 participants, was closed and completed i...

Investors should keep their eyes on the global nanotechnology market, which was valued at USD 3.78 billion in 2022 and is expected to reach USD 74.1 billion by 2032, growing at a CAGR of 34.5% during

NanoViricides (NYSE-A:NNVC) announced that a Phase 1 trial of its investigational therapeutic NV-387 has been completed. The company, a leader in broad-spectrum antiviral nanomedicines, is developing

SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of

NanoViricides (NYSE-A:NNVC) said it is making good progress in its antiviral drug development program, with strong safety data for its lead candidate NV-CoV-2 and enhanced liquidity measures positioni

SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarte

NanoViricides (NYSE-A:NNVC) has a platform that shows a versatile and effective approach to antiviral therapy, with potential applications that target a broad spectrum of viral diseases. The clinical

NanoViricides (NYSE-A:NNVC) told investors it believes that the strong safety and tolerability of its NV-CoV-2 oral drug products containing the active ingredient NV-387 shows that they have implicati

NanoViricides (NYSE-A:NNVC) has earned a ‘Buy' rating and a $6.50 price target from EFHutton analysts after the company released positive safety results from its Phase 1a/1b clinical study involving

SHELTON, CT / ACCESSWIRE / January 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicine

NanoViricides (NYSE-A:NNVC) has successfully wrapped up the first phase of a human clinical trial for its broad-spectrum antiviral drug, NV-CoV-2. The company said that the drug was well-tolerated, wi

NanoViricides (NYSE-A:NNVC) said it exited the third quarter with enough cash on hand to progress clinical trials involving its lead drug candidate NV-CoV-2 for SARS-CoV-2 which causes COVID. NV-CoV-2

NanoViricides (NYSE-A:NNVC) has announced that its broad-spectrum antiviral drug candidate NV-387 in development for MPox and Smallpox was shown to be “highly effective” for these indications in a